DIABETIC ANGIOPATHY «PAINFUL» POINTS: FOCUS ON HYPERTRIGLYCERIDEMIA AND FENOFIBRATE POTENTIAL


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper discusses the problem of prevention and treatment of diabetes mellitus (DM) complications. The analysis indicates that diabetic vascular complications have specific pathogenic features associated with their locations. Evidence from numerous studies showed that fenofibrate exerts anti-inflammatory and antioxidant effects by modulating the PPARγ receptor activity. Activation of vascular cell PPAR receptors reduces the activity of inflammatory markers such as C-reactive protein, tumor necrosis factor a, interleukin-6, fibrinogen and others. Given the multifaceted spectrum of fenofibrate effect, these advantages ultimately reduce the risk of development and progression of micro- and macrovascular complications of diabetes

Full Text

Restricted Access

About the authors

L. A Rujatkina

Email: larut@list.ru
Novosibirsk State Medical University of Minzdrav of Russia MD, Prof. Novosibirsk

D. S Rujatkin

Novosibirsk State Medical University of Minzdrav of Russia Novosibirsk

S. A Zemljanuhina

Polyclinic №2 of Road Hospital at the Station Novosibirsk-the-Main of the Russian Railways Novosibirsk

References

  1. Шестакова М., Лепетухин А.Е., Кварацхелия М.В. и др. Ведение больных сахарным диабетом с терминальной хронической почечной недостаточностью на диализе. Методические указания № 2004/38. М., 2004. 40 с.
  2. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардионефропротекции. Клиническая фармакология и терапия. 2014;23(3):4-27.
  3. Руяткина Л. А., Яхонтов Д. А., Ахмерова Е.В. Функциональное состояние почек и эндотелийзависимая вазодилатация при артериальной гипертонии в сочетании с сахарным диабетом 2 типа. Медицина и образование в Сибири. 2014;2. Доступно по: http://www.ngmu.ru/cozo/mos/eng/arti-cle/text_full.php?id=1357 Ссылка активна на 16.05.2015.
  4. National Diabetes Statistics, 2011. National Diabetes Information Clearinghouse; 2011. Available from: https://nei.nih.gov/eyedata.
  5. Lee W.J., Sobrin L., Kang M.H., Seong M., Kim Y.J., Yi J.H., Miller J.W., Cho H.Y. Ischemic Diabetic Retinopathy as a Possible Prognostic Factor for Chronic Kidney Disease Progression. Eye (Lond). 2014;28(9):1119-25.
  6. Tesfaye S. Diabetic Neuropathy: New Insights With Professor Solomon Tesfaye [Internet]. Medscape Diabetes & Endocrinology; [cited 2014 September 23]. Available from: http:// www.medscape.com/viewarticle/832167.
  7. Gubitosi-Klug R.A. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Summary and Future Directions/Diabetes Care. 2014;37(1):44-9.
  8. Callaghan B.C., Little A.A., Feldman E.L., Hughes R.A. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst. Rev. 2012;6:CD007543.
  9. Руяткина Л.А., Руяткин Д.С., Березовская Г.А. Гипогликемии в патогенезе сердечно-сосудистого риска. Фарматека. 2013;6:15-21.
  10. Дедов И.И., Шестакова М. В., Галстян Г.Р. Алгоритмы специализированной медицинской помощи больным сахарным диабетом, 7 выпуск. Сахарный диабет. 2015;18(1S).
  11. Singleton J.R., Smith A.G., Russell J.W., Feldman E.L. Microvascular complications of impaired glucose tolerance. Diabetes. 2003; 52(12):2867-73.
  12. Tucker M.E. Novel Eye Measure Finds Neuropathy in Prediabetes [Internet]. Medscape Medical News; [cited 2014 July 09]. Available from: http://www. medscape. com/viewarticle/828016.
  13. Аветисов С.Э., Егорова Г.Б. Возможности конфокальной микроскопии. РМЖ. Клин. офтальмол. 2006;7(2):45-9.
  14. Tucker M.E. Corneal Microscopy Detects Diabetic Autonomic Neuropathy [Internet]. Medscape Medical News; [cited 2014 September 30]. Available from: http://www.medscape.com/ viewarticle/832560.
  15. Tesfaye S., Chaturvedi N., Eaton S.E., Ward J.D., Manes C., lonescu-Tirgoviste C., Witte D.R., Fuller J.H. Vascular Risk Factors and Diabetic Neuropathy. N. Engl. J. Med. 2005; 352:341-50.
  16. Dorsey R.R., Eberhardt M.S., Gregg E. W., Geiss L.S. Control of risk factors among people with diagnosed diabetes, by lower extremity disease status. Prev. Chronic. Dis. 2009;6(4):A114.
  17. Gaude P., Vedel P., Larsen N., Jensen G.V., Parving H.H., Pedersen O. Multifactorial interventions and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003;348(5):383-93.
  18. Subedi B.H., et al. The Role of Statins in Diabetes Treatment. Diabetes Spectrum. 2013;26(3):156-64.
  19. Sattar N., Preiss D., Murray H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-42.
  20. Pick A., Clark J., Kubstrup C., Levisetti M., Pugh W., Bonner-Weir S., Polonsky K.S. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes. 1998;47(3):358-64.
  21. Unger R.H. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes. 1995;44(8):863-70.
  22. Poitout V., Robertson R.P. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr. Rev. 2008;29(3):351-66.
  23. Tenenbaum A., Klempfner R., Fisman E.Z. Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc. Diabetol. 2014;13(1):159.
  24. Robertson R.P., Harmon J., Tran P.O., Poitout V. β-Cell Glucose Toxicity, Lipotoxicity, and Chronic Oxidative Stress in Type 2 Diabetes. Diabetes. 2004;53(Suppl. 1):S119-24.
  25. Li N., Frigerio F., Maechler P. The sensitivity of pancreatic beta-cells to mitochondrial injuries triggered by lipotoxicity and oxidative stress. Biochem. Soc. Trans. 2008;36(Pt. 5):930-34.
  26. Tomlinson D.R., Gardiner N.J. Glucose neurotoxicity. Nat. Rev. Neurosci. 2008;9(1):36-45.
  27. Padilla A., Descorbeth M., Almeyda A.L., Payne K., De Leon M. Hyperglycemia magnifies Schwann cell dysfunction and cell death triggered by PA-induced lipotoxicity. Brain Res. 2011;1370:64-79.
  28. Cermenati G., Abbiati F., Cermenati S., Brioschi E., Volonterio A., Cavaletti G., Saez E., De Fabiani E., Crestani M., Garcia-Segura L.M., Melcangi R.C., Caruso D., Mitro N. Diabetes-induced myelin abnormalities are associated with an altered lipid pattern: protective effects of LXR activation. J. Lipid. Res. 2012;53(2):300-10.
  29. Xu L., Tang D., Guan M., Xie C., Xue Y.Effect of High-Fat Diet on Peripheral Neuropathy in C57BL/6 Mice. Int. J. Endocrinol. 2014;2014:305205.
  30. Isomaa B., Henricsson M., Almgren P., Tuomi T., Taskinen M.R., Groop L. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia. 2001;44(9):1148-54.
  31. Wiggin T.D., Sullivan K.A., Pop-Busui R.T., Amato A., Sima A.A., Feldman E.L. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes. 2009;58(7):1634-40.
  32. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glasziou P., Drury P., Kesаniemi Y.A., Sullivan D., Hunt D., Colman P., d'Emden M., Whiting M., Ehnholm C., Laakso M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849-61.
  33. Демидова Т.Ю., Трахтенберг Ю.А. Современные возможности терапии диабетической ретинопатии. Сахарный диабет. 2014;3:122-28.
  34. Аметов А.С., Лысенко М.А. Роль и место фенофибрата в комплексной многофакторной терапии диабетической периферической нейропатии при сахарном диабете типа 2. Эндокринология. 2013;3. Доступно по: http://endocrine-nmo.geotar. ru/ru/jarticles_endo/106.html?SSr=0001337 8f708ffffffff27c 07df0513080000-2ef5.
  35. Glaser B.M., D'Amore P.A., Michels R.G., Brunson S.K., Fenselau A.H., Rice T., Patz A. The demonstration of angiogenic activity from ocular tissues. Preliminary report. Ophthalmology. 1980;87(5):440-46.
  36. Коненков В.И., Климонтов В.В. Ангиогенез и васкулогенез при сахарном диабете: новые концепции патогенеза и лечения сосудистых осложнений. Сахарный диабет. 2012;4:17-27.
  37. Osaadon P., Fagan X.J., Lifshitz T., Levy Disclosures J. A Review of Anti-VEGF Agents for Proliferative Diabetic Retinopathy. Eye. 2014;28(5):510-20.
  38. Panigrahy D., Kaipainen A., Huang S., Butterfield C.E., Barnеs C.M., Fannon M., Laforme A.M., Chaponis D.M., Folkman J., Kieran M.W. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc. Natl. Acad. Sci., USA. 2008;105(3):985-90.
  39. Chen N.Y., Hu Y., Lin M., Jenkins A.J., Keech A.C., Mott R., Lyons T.J., Ma J.X. Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models. Diabetes. 2013;62(1):261-72.
  40. Salehi E., Khazaei M., Rashidi B. Role of fenofibrate in restoring angiogenesis in diabetic and control hind limb ischemic rats. Gen. Physiol. Biophys. 2012;31(3):255-60.
  41. Salehi E., Khazaei M. Fenofibrate, a peroxisome proliferator-activated receptor alpha, improves myocardial capillary density in diabetic rats. J. Pak. Med. Assoc. 2012;62(3 Suppl. 2):S9-12.
  42. Soares R. Angiogenesis in diabetes. Unraveling the angiogenic paradox. Open Circul. J. 2010;3(2):3-9.
  43. Ginsberg H.N., Illingworth D.R. Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus. Am. J. Cardiol. 2001;88(6A):9H-15.
  44. Jagla A., Schrezenmeir J. Postprandial triglycerides and endothelial function. Exp. Clin. Endocrinol. Diabetes. 2001;109(4):S533-47.
  45. Meilin E., Aviram M., Hayek T. Insulin increases macrophage triglyceride accumulation under diabetic conditions through the down regulation of hormone sensitive lipase and adipose triglyceride lipase. Biofactors. 2011 37(2):95-103.
  46. Александров А.А. Сахарный диабет: болезнь «взрывающихся» бляшек. Consilium Medicum. 2001;1:4-10.
  47. Silveira A. Postprandial triglycerides and blood coagulation. Exp. Clin. Endocrinol. Diabetes. 2001;109(4):S527-32.
  48. Стаценко М.Е., Туркина С.В., Толстов С.Н. Место p-FOX-ингибиторов свободных жирных кислот в комбинированной терапии сердечно-сосудистых осложнений у больных сахарным диабетом 2-го типа. Российский кардиологический журнал. 20112(88):102-10.
  49. Cavallero E., Piolot A., Jacotot B. Postprandial lipoprotein clearance in type 2 diabetes: fenofibrate effects. Diabete Metab. 1995; 21(2):118-20.
  50. Keating G.M., Croom K.F. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs. 2007;67(1):121-53.
  51. Keating G.M. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. Am. J. Cardiovasc. Drugs. 2011;11(4):227-47.
  52. Tenenbaum A., Fisman E.Z. «If it ain't broke, don't fix it»: a commentary on the positivenegative results of the ACCORD Lipid study. Cardiovasc. Diabetol. 2010;9:24.
  53. Кошель Л.В., Романцова Т.И. Роль Фенофибрата в лечении микрососудистых осложнений сахарного диабете 2 типа. Сахарный диабет. 2009;4:99-103.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies